Acute Ischemic Stroke
Conditions
Brief summary
This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke
Interventions
Administered by intravenous infusion.
DRUGPlacebo
Administered by intravenous infusion.
DRUGLT3001 Drug:low dose
Administered by intravenous infusion.
Sponsors
Shanghai Pharmaceuticals Holding Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects aged between 18 and 80 years at screening; 2. Clinical diagnosis of acute ischemic stroke that causes evaluable neurological impairment; 3.4 points ≤ NIHSS score ≤ 25 points at randomization; 4.Subjects who are able to receive the investigational drug within 24 hours after the onset of stroke; 5.Female subjects of childbearing potential or male subjects whose sexual partner are women of childbearing potential have no pregnancy plan and voluntarily take effective contraceptive measures during the study period and for 3 months after the last dose; 6.All subjects sign the informed consent form by themselves or their guardians after receiving complete study information.
Exclusion criteria
1. Subjects have received or plan to receive endovascular treatment and/or intravenous thrombolytic therapy recommended by Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2018 during this onset period; 2. Presence of disturbances of consciousness at screening and NIHSS 1a ≥ 2 points; 3. Neurological signs have improved rapidly and spontaneously at screening; 4. Subjects who have used or are using protocol-prohibited medications after the onset; 5. Subjects with pre-stroke disability; 6. Subjects with intracranial hemorrhagic diseases, tumor in brain parenchyma, arteriovenous malformation, aortic arch dissection, other central nervous system lesions that may increase the risk of hemorrhage, or imaging evidence for arterial aneurysm requiring treatment; 7. Massive infarction on imaging; 8. Patients who are unable to cooperate due to epileptic seizure at the onset of stroke or other concomitant mental disorders or are unwilling to cooperate; 9. Systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 100 mmHg after active antihypertensive therapy; 10. Acute hemorrhage tendency; 11. Blood glucose level \< 50 mg/dL or \> 400 mg/dL; 12. Active visceral hemorrhage; 13. Lactating or pregnant subjects, or women of childbearing potential with positive pregnancy test results; 14. International normalized ratio \> 1.7 or prothrombin time \> 15 s; 15. Subjects with a history of serious hypersensitivity; 16. Subjects who experienced AIS, ICH, acute myocardial infarction or serious head trauma before screening; 17. Subjects who underwent any major surgery before screening; 18. Subjects with a history of active digestive ulcer before screening; 19. Subjects who experienced hemorrhagic disease before screening; 20. Subjects who underwent arterial puncture at the site not easy for hemostasis by compression before screening; 21. Serious hepatic impairment or serious renal insufficiency; 22. Subjects who have participated in another investigational study and used investigational product before screening; 23. Other conditions unsuitable for participation in this study determined by the Investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence Adverse Events | Approximately 2 years | Adverse event type, incidence, duration, correlation with study drug |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of subjects by mRS（Modified Rankin Scale） score (0 - 2) | Day 30 and Day 90 after the first dose | Proportion of subjects by mRS score (0 - 2) |
| Proportion of subjects with an NIHSS（National Institute of Health stroke scale ） score of ≤ 1 point and/or with a decrease of ≥ 4 points from baseline in NIHSS score | Day 14 after the first dose | Proportion of subjects with an NIHSS score of ≤ 1 point and/or with a decrease of ≥ 4 points from baseline in NIHSS score |
| Absolute change from baseline in NIHSS score | Day 3、Day 7、Day 14 and Day 30 after the first dose | Absolute change from baseline in NIHSS score |
| Proportion of subjects with a BI（Barthel index） score of ≥ 95 points and ≥ 75 points | Day 30 and Day 90 after the first dose | Proportion of subjects with a BI score of ≥ 95 points and ≥ 75 points |
Countries
China
Contacts
CONTACTYongjun Wang
Outcome results
None listed